Overview

Comparing Antipsychotic Medications in LBD Over Time

Status:
Recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine whether treatment with pimavanserin or quetiapine is associated with a greater improvement in psychosis when used in a routine clinical setting to treat hallucinations and/or delusions due to Parkinson's disease (PD) or dementia with Lewy bodies (DLB) - collectively referred to as Lewy body disease (LBD).
Phase:
Phase 4
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio
Collaborator:
Alzheimer's Association
Treatments:
Pimavanserin
Quetiapine Fumarate